- Home
- FGNX vs INMB Comparison
FGNX vs INMB Comparison
Compare FGNX & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FGNX | INMB |
|---|---|---|
| Founded | 1932 | 2015 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 40.4M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | FGNX | INMB |
|---|---|---|
| Price | $6.79 | $1.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $35.00 | $5.40 |
| AVG Volume (30 Days) | 72.7K | ★ 220.1K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | $650.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $1.59 | $1.09 |
| 52 Week High | $18.42 | $11.64 |
Technical Indicators
Market Signals| Indicator | FGNX | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 47.50 |
| Support Level | $6.52 | $1.15 |
| Resistance Level | $7.17 | $1.48 |
| Average True Range (ATR) | 0.42 | 0.09 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 55.60 | 16.98 |
Price Performance
Historical ComparisonAbout FGNX Fundamental Global Inc.
FG Nexus Inc operates through two primary segments: Digital Assets and Merchant Banking, with Digital Assets contributing the majority of revenue. The Company functions as a digital asset treasury, mainly holding Ethereum (ETH) and exploring opportunities in the tokenization of real-world assets, leveraging ETH as the foundation for digital finance, stablecoins, DeFi, and tokenized assets. The Merchant Banking segment offers strategic, administrative, and regulatory support to newly formed SPACs through the Company's SPAC platform.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.